Abstract |
The beta-lactam family of antimicrobials, in particular penicillins and cephalosporins, is the mainstay of treatment for community-acquired infections. However, the emergence of resistant isolates to these agents has raised concerns regarding the continued efficacy of existing therapies. Resistance to beta-lactams is most commonly expressed by the microbial production of beta-lactamases that hydrolyze the beta-lactam ring. Three further resistance mechanisms include conformational changes in penicillin-binding proteins (PBPs); permeability changes in the outer membrane; and active efflux of the antimicrobial. In addition to the pre-requisite efficacy and tolerability profiles, new beta-lactams should address these four resistance mechanisms. Overcoming resistance may be a serendipitous event or arrived at by design. A unique synthetic beta-lactam class, which demonstrates promise in terms of its activity against the range of bacteria responsible for community-acquired infections and its inherent stability to hydrolysis by beta-lactamases, is the penems. This discrete class of hybrid molecules combines properties from the penicillin (penam) and cephalosporin (cephem) beta-lactam classes. Faropenem is an example of a penem with a broad spectrum of activity designed to address these resistance issues.
|
Authors | S G B Amyes |
Journal | Journal of chemotherapy (Florence, Italy)
(J Chemother)
Vol. 15
Issue 6
Pg. 525-35
(Dec 2003)
ISSN: 1120-009X [Print] England |
PMID | 14998075
(Publication Type: Comparative Study, Journal Article, Review)
|
Chemical References |
|
Topics |
- Biological Availability
- Community-Acquired Infections
(drug therapy, microbiology)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Resistance, Multiple, Bacterial
- Humans
- Microbial Sensitivity Tests
- Sensitivity and Specificity
- beta-Lactam Resistance
- beta-Lactams
(pharmacokinetics, therapeutic use)
|